Early Postoperative ^{18}F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

Lisbeth Marner[1], Karsten Nysom[2], Astrid Sehested[2], Lise Borgwardt[1], René Mathiasen[2], Otto Mølby Henriksen[1], Michael Lundemann[1], Per Munck af Rosenschöld[3], Carsten Thomsen[4,5], Lars Bøgeskov[6], Jane Skjøth-Rasmussen[6], Marianne Juhler[6], Anders Kruse[7], Helle Broholm[8], David Scheie[8], Torsten Lauritsen[9], Julie Lyng Forman[10], Peder Skov Wehner[11], Liselotte Højgaard[1], and Ian Law[1]

[1]Department of Clinical Physiology, Nuclear Medicine, and PET, Copenhagen University Hospital, Rigshospitalet, Denmark; [2]Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark; [3]Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark; [4]Department of Diagnostic Radiology, Copenhagen University Hospital, Rigshospitalet, Denmark; [5]Department of Radiology, Zealand University Hospital, Køge, Denmark; [6]Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Denmark; [7]Department of Orthopaedic Surgery, Copenhagen University Hospital, Rigshospitalet, Denmark; [8]Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Denmark; [9]Department of Anaesthesiology, Copenhagen University Hospital, Rigshospitalet, Denmark; [10]Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; and [11]Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark

Complete resection is the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection of residual tumor may be misleading because of MRI signal changes caused by the operation. PET imaging with amino acid tracers in adults increases the diagnostic accuracy for brain tumors, but the literature in pediatric neurooncology is limited. A hybrid PET/MRI system is highly beneficial in children, reducing the number of scanning procedures, and this is to our knowledge the first larger study using PET/MRI in pediatric neurooncology. We evaluated if additional postoperative ^{18}F-fluoro-ethyl-tyrosine (^{18}F-FET) PET in children and adolescents would improve diagnostic accuracy for the detection of residual tumor as compared with MRI alone and would assist clinical management. **Methods:** Twenty-two patients (7 male; mean age, 9.5 y; range, 0–19 y) were included prospectively and consecutively in the study and had 27 early postoperative ^{18}F-FET PET exams performed preferentially in a hybrid PET/MRI system (NCT03402425). **Results:** Using follow-up (93%) or reoperation (7%) as the reference standard, PET combined with MRI discriminated tumor from treatment effects with a lesion-based sensitivity/specificity/accuracy (95% confidence intervals) of 0.73 (0.50–1.00)/1.00 (0.74–1.00)/0.87 (0.73–1.00) compared with MRI alone: 0.80 (0.57–1.00)/0.75 (0.53–0.94)/0.77 (0.65–0.90); that is, the specificity for PET/MRI was 1.00 as compared with 0.75 for MRI alone (P = 0.13). In 11 of 27 cases (41%), results from the ^{18}F-FET PET scans added relevant clinical information, including one scan that directly influenced clinical management because an additional residual tumor site was identified. ^{18}F-FET uptake in reactive changes was frequent (52%), but correct interpretation was possible in all cases. **Conclusion:** The high specificity for detecting residual tumor suggests that supplementary ^{18}F-FET PET is relevant in cases where reoperation for residual tumor is considered.

Central nervous system tumors are the most common solid tumors in childhood, with the highest incidence of cancer-related death in children and adolescents (1,2). Moreover, severe late effects of tumor and its treatment are frequently seen in this group (3). If possible, complete resection is the primary treatment for most tumor types, and it is widely accepted that the degree of resection has a significant impact on prognosis (4–6). MRI 0–72 h after surgery is the current method of choice for assessing the degree of resection. However, signal changes on postoperative MRI can also be caused by tissue reaction to surgery; for example, bleeding, hemostatic adsorbents, inflammation, edema, ischemia, or signal artifacts from metal implants can disturb the MRI interpretation. Addition of PET imaging may help differentiate residual tumor from postoperative changes. Although brain tumor imaging using the glucose analog ^{18}F-FDG is hampered by a high physiologic uptake in gray matter, imaging with amino acid analogs such as ^{11}C-methionine, ^{18}F-fluoro-phenylalanine, or ^{18}F-fluoro-ethyl-tyrosine (^{18}F-FET) has been shown to delineate tumor tissue from normal brain tissue with a high accuracy, especially in non–contrast-enhancing lesions (7–10), and residual PET tracer uptake after operation predicts shorter survival in high-grade gliomas (11). However, significant uptake of amino acid analogs can also be observed in nonneoplastic and acute inflammatory lesions (12).

Several studies in adults found an increased sensitivity for residual tumor after surgery for glioblastoma using ^{18}F-FET PET compared with MRI (13,14). Tscherpel et al. reported valuable diagnostic information of brain stem and spinal cord imaging using ^{18}F-FET PET (15). In children, only 2 retrospective studies

are available. A high clinical value of postoperative ^{11}C-methionine or ^{18}F-FDG PET was found in 20 pediatric patients with possible residual tumor ([16]), and Dunkl et al. reported agreement between MRI and ^{18}F-FET PET findings postoperatively in another 10 children ([17]).

Using a hybrid PET/MRI system is preferable in children to reduce the number of scanning procedures. We evaluated the added clinical value of postoperative ^{18}F-FET PET in children and adolescents after surgery for a brain or spinal cord tumor if possible using simultaneous acquisition in a hybrid PET/MRI system. Further, we analyzed if ^{18}F-FET PET/MRI showed increased sensitivity, specificity, and accuracy for detecting residual tumor as compared with MRI alone. We hypothesized a higher sensitivity, specificity, and accuracy for the detection of residual tumor, which could assist a difficult clinical decision on whether to reoperate as well as the delineation of tumor or the identification of additional tumor lesions.

MATERIALS AND METHODS

The study is part of a larger study of ^{18}F-FET PET/MRI on primary central nervous system tumors in children and adolescents in various clinical situations. The study was approved by the regional ethical committee (approval H-6-2014-095) and registered at clinicaltrials.gov (NCT03402425).

Patient Inclusion

Inclusion criteria were diagnosis of a central nervous system tumor before the age of 18 y and planned partial or total resection of the tumor. In the study period from March 2015 to October 2017, 28 children and adolescents were included prospectively and consecutively, and written informed consent was provided by all patients or their parents (in patients < 18 y). Six patients were excluded (because of discontinuation of the PET scan, unsuccessful tracer production, or preoperative ^{18}F-FET PET showing no tracer uptake in tumor), leaving 22 children and adolescents (Table 1) with a total of 27 ^{18}F-FET PET scans performed early after surgery (median, 48 h; range, 1–15 d), as 5 patients had a reoperation. Anesthesia was necessary in 8 cases. When possible, preoperative ^{18}F-FET PET/MRI was also performed (*n* = 18). During the study period, another 30 operations for a primary pediatric brain tumor were performed without inclusion in the study because of parents or child declining inclusion (*n* = 4), unavailability of anesthesia (*n* = 13), emergency surgery (*n* = 4), social problems (*n* = 4), or other reasons (*n* = 5).

Imaging

The MRI protocol for the hybrid PET/MRI system 3-T Siemens Biograph mMR included a 3-dimensional T1 magnetization-prepared rapid gradient echo sequence before and after contrast agent; T2 fluid-attenuated inversion recovery, diffusion weighted imaging; and T2 BLADE (proprietary name for periodically rotated overlapping parallel lines with enhanced reconstruction in MR systems from Siemens Healthcare). Supplemental Table 1 provides a detailed description of the MRI protocol (supplemental materials are available at http://jnm.snmjournals.org). Three postoperative scans and 9 preoperative scans were performed on standalone MRI systems at the Department of Diagnostic Radiology at Copenhagen University Hospital Rigshospitalet or the Department of Radiology at University Hospital Odense using similar protocols.

A 40-min dynamic PET emission scan in list mode was obtained using the PET/MRI system (*n* = 24) or a Biograph TruePoint PET/CT (*n* = 3) (Siemens) initiated simultaneously with a 3 MBq/kg injection of ^{18}F-FET preceded by 4 h of fasting for proteins. To ensure compliance, 2 patients had the scan time reduced. An overview of hybrid PET/MRI protocols for brain or spinal tumors was previously published by Henriksen et al. ([18]). The static PET images (20–40 min after injection) were reconstructed into a 344 × 344 matrix (voxel size, 0.8 × 0.8 × 2 mm) using 3-dimensional iterative ordered-subset expectation maximization (4 iterations, 21 subsets) and applying a 5-mm gaussian filter. Low-dose CT of the brain (120 kV, 30 mAs, 5-mm slice width) was used for attenuation correction obtained on a separate PET/CT scanner ([19]). The spinal cord acquisitions were attenuation-corrected with standard MRI-based attenuation maps derived using the Dixon sequence ([20]). Movement registration during the scan was performed as described previously ([18]).

Image Analysis

The PET data were evaluated as part of daily routine by a nuclear medicine specialist experienced with neurooncology using a Leonardo workstation (Siemens). The static PET image was evaluated for ^{18}F-FET uptake in tumor relative to unaffected gray matter as described previously ([17]). In short, the background ^{18}F-FET activity uptake was estimated as the average activity concentration in a large cortical region at the level of the centrum semiovale. The maximal tumor-to-background ratio was estimated and the tumor delineated with a threshold for metabolic activity in tumor of 1.6 times the background ([21]). For spinal tumors, interpretation was based on visual analysis only as no cortical background region was available. For dynamic analysis, a volume of interest (0.2–0.6 cm^3) was defined at the static image and transferred to the entire dynamic dataset to extract the time–activity curve. The curve pattern was rated as type 1 (steady increasing, benign lesion or low grade), type 2 (plateau after 20–40 min, intermedium), or type 3 (decreasing after an early peak < 20 min, malignant) as defined previously ([17,22,23]). The discrimination between postoperative treatment changes and active disease was an integrated decision based on all available information including the preoperative scan if available and the combined evaluation of PET and MRI, as described in the practice guidelines for amino acid PET imaging of gliomas ([24]). Reactive changes were deemed more likely when maximal tumor-to-background ratio was less than 2.0, curve pattern was type I, uptake was outside the preoperative tumor border, diffuse uptake was along the cortex or the margin of the resection cavity, or uptake was in areas of vascular structures or postoperative changes on MRI, including hemorrhages or infarcts. An additional masked reading was performed by a nuclear medicine specialist experienced with neurooncology to assess the interrater variability.

Evaluation

The added clinical value of the PET scan was assessed at a weekly multidisciplinary childhood central nervous system tumor board. Initially, possible residual tumor was assessed from MRI by neuroradiologists experienced with pediatric brain tumors, and a treatment plan was decided while masked to the results of ^{18}F-FET PET. It was rated whether the MRI was sufficient for deciding the treatment plan or whether a supplementary ^{18}F-FET PET scan was warranted, for example, because of equivocal MRI. Subsequently, the results from the ^{18}F-FET PET imaging were revealed, and it was rated whether the ^{18}F-FET PET scan had no impact, added new information (e.g., residual tumor mass, different tumor borders), or influenced clinical management. These initial scorings was corroborated at later review meetings between clinicians, a neuroradiologist experienced in pediatric neurooncology, and a nuclear medicine specialist to ensure the validity.

As biopsy or reoperation to remove possible residual tumor was performed only if this procedure was clinically indispensable, the existence of residual tumor was histologically confirmed only in 2 cases by immediate reoperation and in the remaining cases by clinical follow-up and MRI. In equivocal cases (*n* = 12), the final assessment

TABLE 1

Results of Early Postoperative ^{18}F-FET PET and MRI in Children and Adolescents Undergoing Central Nervous System Tumor Surgery

Patient no.	Sex/age (y)	Diagnosis	WHO grade	Location	Postoperative assessment of residual tumor sites (no. sites) MRI	Postoperative assessment of residual tumor sites (no. sites) PET/MRI (TBR$_{max}$)	TBR$_{max}$ in reactive changes	Impact of PET	Final assessment of residual tumor (n)	Follow-up (mo)
1	F/13/14*	DMG	IV	Central	1 (−CE)	None†	1.8	None	1 (−CE)	RCT. Distant recurrence (4)
		DMG	IV	Fossa posterior	1 (+CE)	1 (3.1)	2.6	None	1 (+CE)	RT. Death (3)
2	F/11	AT/RT	IV	Frontotemporal	None	None	1.9	C	None	RCT. Distant recurrence (6). Death (8)
3	M/3/3*	AT/RT	IV	Intraventricular	1 (+CE)	2 (2.3/1.8)	1.8	A	2 (+CE)	Reoperation
		AT/RT	IV	Intraventricular	None	None	<1.6	C	None	RCT. Stable (32)
4	F/9/10*	HGNET	IV	Temporoparietal	None	None	2.0	None	None	RT. Distant recurrence (15)
		HGNET	IV	Parietal lobe	None	None	<1.6	None	None	RT. Stable (15)
5	M/15	NG	IV	Pineal body	None	None	1.9	C	None	RCT. Stable (30)
6	F/14/14*	Anaplastic PA	—	Fossa posterior	None†	None†	1.8	None	None	Local recurrence (6)
		Anaplastic PA	—	Fossa posterior	None†	1 (1.8)	2.2	B	1 (+CE)	RT. Stable (20)
7	F/14	Anaplastic PA	—	Central	1 (+CE)	1 (2.2)	<1.6	C	1 (+CE)	RCT
8	M/6/6*	Ep	II	Fossa posterior	2 (+CE/+CE)	1 (2.2)	2.1	B	1 (+CE)	Reoperation
		Ep	II	Fossa posterior	None	None	<1.6	C	None	RCT. Stable (34)
9	F/6	JXG	—	Frontal lobe	1 (+CE)	1 (2.1)	2.2	D	1 (+CE)	CT. Regression (24)
10	F/8	PXA	II	Temporal lobe	2 (+CE/+CE)†	1 (2.0)†	2.0	None	1 (+CE)	Stable (24)
11	M/0	PP	II	Intraventricular	None	None	<1.6	None	None	Stable (12)
12	F/8	Atypical GG	I-II	Parietooccipital	1 (+CE)	None	1.8	None	1 (+CE)	Stable (24)
13	F/10	PA	I	Fossa posterior	None	None	<1.6	None	None	Local recurrence (9)
14	F/8	PA	I	Temporal lobe	1 (+CE)	None	<1.6	B	None	Stable (9)
15	F/4	PA	I	Fossa posterior	1 (+CE)	1 (2.3)	<1.6	None	1 (+CE)	Stable (36)
16	M/15	PA	I	Fossa posterior	2 (−CE/+CE)	None	<1.6	B	1 (−CE)	Stable (36)
17	F/10	PA	I	Fossa posterior	1 (+CE)	1 (2.0)	<1.6	None	1 (+CE)	Local recurrence. Reoperation (32)
18	M/7	PA	I	Fossa posterior	None	None	<1.6	None	1 (−CE)	Stable (12)
19	M/7	PA	I	Fossa posterior	None	None	1.8	None	None	Stable (9)
20	F/14	GG	I	Temporal lobe	1 (+CE)	1 (2.9)	<1.6	None	1 (+CE)	Progression (18). CT
21	F/19	GG	I	Temporal lobe	None	None	1.9	None	None	Stable (24)
22	F/12	GG	I	Spinal	None	None	<1.6	None	None	Stable (3)

*Age at second scan.

†Equivocal residual tumor. noted number of tumor sites is based on forced decision.

TBR$_{max}$ = maximal tumor-to-background ratio; CE = contrast enhancement; PA = pilocytic astrocytoma; AT/RT = atypical teratoid/rhabdoid tumor; Ep = ependymoma; DMG = diffuse midline glioma H3 K27 M mutated; NG = nongerminoma; GG = ganglioglioma; HGNET = central nervous system high-grade neuroepithelial tumor with MN1 alteration; PXA = pleomorphic xanthoastrocytoma; JXG = juvenile xanthogranuloma; PP = atypical plexus choroideus papilloma; impact of PET: A = influenced clinical management; B = added important clinical information; C = supported clinical decision; D = baseline for later scan that influenced clinical management; RCT = radiochemotherapy; RT = radiotherapy; CT = chemotherapy.

TABLE 2
Lesion-Based Outcome Parameters Corrected for Multiple Lesions Within Each Subject

Parameter	MRI	95% CI	PET/MRI	95% CI	*P*
Sensitivity	0.80	0.57–1.00	0.73	0.50–1·00	1.00
Specificity	0.75	0.53–0.94	1.00	0.74–1.00	0.13
Accuracy	0.77	0.65–0.90	0.87	0.73–1.00	0.53

CI = confidence interval.

Positive predictive value and negative predictive value (PPV/NPV) were 0.75/0.80 for MRI and 1.00/0.80 for PET/MRI. Interrater variability for PET/MRI was low, with Cohen κ of 0.86, and identical sensitivity, specificity, and accuracy were found for second reading.

of possible residual tumor was based on a consensus multidisciplinary evaluation of the course of disease.

Statistics

Sensitivities, specificities, and accuracies between MRI alone and PET/MRI were compared using McNemar testing based on the exact binomial distribution. To correct for a possible correlation between lesions belonging to the same patient, an additional nonparametric permutation test was performed. Bootstrap confidence intervals were computed by resampling patients 50,000 times. However, as the specificity of PET/MRI was found to be 100%, a confidence interval was obtained from the binomial distribution using the number of patients as a conservative estimate of the effective sample size. A Fisher exact test was used to test for significant differences of tracer uptake in reactive changes after 24 h versus later. All analyses were performed with R statistical software, version 3.4.1. Interrater variability was assessed with Cohen κ.

RESULTS

Diagnostic Accuracy

Table 1 shows the results. None of the PET scans were rated necessary for clinical decision making; that is, no clinically relevant information from the PET scan was prospectively anticipated. This rating was due to the lack of expected clinical consequences, as reoperation was not relevant in the 2 scans with equivocal MRI. In 14 (52%) cases, the patient had residual tumor based on immediate reoperation or follow-up leading to a sensitivity/specificity/accuracy of 0.79/0.92/0.85 for MRI alone and 0.71/1.00/0.85 for PET/MRI. Four subjects had more than one evaluated lesion, and the lesion-based sensitivity/specificity/accuracy with 95% confidence intervals can be found in Table 2. Figure 1 shows an example of a patient with more than one evaluated lesion.

Clinical Impact

PET directly influenced clinical management in one patient (patient 3), as an additional small lesion, not visible on MRI, was identified by PET (Fig. 2), prompting resection of an extra tumor site at reoperation. In an additional 10 cases (37%), PET added important clinical information or assisted a difficult clinical decision (Table 1), although no impact was anticipated beforehand. In most cases of residual tumor, no immediate reoperation was indicated because of a relative benign pathology or a position in vital or eloquent brain areas, and thus PET did not directly change

clinical management even if additional important clinical information from PET was achieved.

Tracer Uptake in Reactive Tissue Changes

Reactive changes with a maximal tumor-to-background ratio above 1.6 were found in 52% of scans (Table 1). Reactive tracer uptake tended to be less likely if scans were performed within 24 h after surgery (31%) than if performed later (71%) ($P = 0.06$). By careful review, it was possible in all cases by forced decision to correctly differentiate tumor from postoperative changes because later MRI scans did not reveal tumor in any of the areas with ^{18}F-FET uptake that had been interpreted as reactive changes. Preoperative PET was available in 18 cases and was important for interpretation of the postoperative scans in 13 cases (72%), as the preoperative scans assisted the identification of new venous infarctions or reactive changes postoperatively. Pre- and postoperative scans of the spinal cord tumor allowed for unambiguous interpretation (Fig. 3).

DISCUSSION

The exact clinical role of PET/MRI in oncology has been the subject of continuous discussion. Emphasis have been given to PET/MRI as a tool for comprehensive assessment of morphology and molecular phenotyping, particularly useful in the pediatric population as one of the key applications (25) to reduce radiation exposure, number of scanning procedures, and image misregistration and to limit the risk and cost of anesthesia (26). However, this is to our knowledge the first larger clinical study using PET/MRI in pediatric neurooncology and the second study in pediatric oncology (27) testifying to the work-flow complexities of this sensitive patient group.

Complete surgical tumor removal of a brain tumor improves the prognosis in most children and adolescents. However, in accordance


FIGURE 1. A 15-y-old boy (patient 16) operated on for pilocytic astrocytoma, WHO grade I. Preoperative scan shows contrast-enhancing (CE) and non–contrast-enhancing lesions and large cyst (arrows). Postoperatively, the 2 lesions are discordant on MRI and PET. Axial view shows contrast-enhancing lesion interpreted as residual tumor on MRI but without ^{18}F-FET activity uptake. This lesion disappeared spontaneously after 3 mo. Coronal view shows non–contrast-enhancing residual tumor without ^{18}F-FET uptake that persisted for 2 y. FLAIR = fluid-attenuated inversion recovery MRI sequence.

FIGURE 2. A 3-y-old boy (patient 3) operated on for atypical teratoid/rhabdoid tumor, WHO grade IV. Large intraventricular contrast-enhancing (CE) tumor mass is seen preoperatively. Postoperatively, MRI identifies contrast-enhancing residual tumor inferiorly in resection cavity (yellow arrow). Additional small residual tumor (red arrow) was identified only by ^{18}F-FET PET. Complete resection was obtained by removing both residual tumor masses. Patient received radiochemotherapy and is in long-term remission. FLAIR = fluid-attenuated inversion recovery MRI sequence.

FIGURE 3. A 12-y-old girl (patient 22) with ganglioglioma, WHO grade I, in spinal cord. Preoperatively, contrast-enhancing (CE) tumor with high ^{18}F-FET activity uptake is seen (arrows). Twenty-four hours postoperatively, resection cavity and changes are seen on MRI sequences. No significant ^{18}F-FET activity uptake is present.

with earlier reports (*28,29*) residual tumor was detected either by immediate reoperation or by clinical follow-up after 52% of the operations. Frequent contrast enhancement on postoperative MRI challenges the identification of true residual tumor, which can lead to unnecessary reoperations. The addition of ^{18}F-FET PET for early postoperative imaging led to a lesionwise specificity of 1.00 as compared with 0.75. Thus, the addition of ^{18}F-FET PET may diminish the risk of a reoperation based on false-positive residual tumor on MRI. The reported sensitivity and specificity for MRI is similar to earlier reports (*30*). Earlier studies of postoperative ^{18}F-FET PET found a higher sensitivity for residual tumor by PET than by MRI (*13,14*), whereas a study of recurrent glioma in adults using ^{18}F-fluorophenylalanine PET in line with our results reported a significant increase in specificity of 0.89 (PET), versus 0.44 (MRI) (*9*).

Clinical Impact

In 41% of the scans, additional important information was obtained, including one case (patient 3) of directly influenced treatment because an additional small tumor lesion identified on the ^{18}F-FET PET scan was removed (Fig. 2), ensuring complete resection. The patient has no signs of recurrence of the atypical teratoid/rhabdoid tumor (WHO grade IV) 32 mo later. Another postoperative scan served as a necessary baseline for later clinical decision making. To our knowledge, this is the first report of prospectively and consecutively collected ^{18}F-FET PET scans early after surgery for brain tumors in children. A previous study of early postoperative ^{11}C-methionine PET or ^{18}F-FDG PET with 20 children (*16*) showed a pronounced clinical impact of PET, with early second-look surgery in 11 patients. However, only children suspected of having residual tumor were included (70% had equivocal MRI results), in contrast to the present study, which included patients consecutively without selection based on MRI findings (7% had equivocal MRI; Table 1).

Reactive Tissue Changes

Postoperative tissue changes hamper the reading of the MRI, and the same is true for ^{18}F-FET PET, with a high fraction (52%) of ^{18}F-FET activity uptake in postoperative reactive changes, especially if the ^{18}F-FET PET is performed more than 24 h after surgery. Frequent ^{18}F-FET uptake in reactive changes due to inflammation is well known (*12*), but in the present study using forced decision, it was possible in all cases to discriminate between residual tumor and postoperative changes.

Limitations

The study contains a relatively high fraction of low-grade gliomas (mainly pilocytic astrocytomas, WHO grade I), for which a conservative approach in cases of residual tumor is common as opposed to high-grade tumors (WHO grade III–IV), in which complete resection is highly prioritized. This reduces the potential clinical impact of the study. Another limitation is the lack of biopsy confirmation of the possible residual tumors. As no clinical consequences were expected, it was deemed unethical to obtain biopsies. Instead we used clinical follow-up and, in difficult cases, consensus reading of the follow-up scans at a formal review meeting. The relatively small number of patients reduces the statistical power of the study, and although a much higher specificity of 1.00 as compared with 0.75 was observed, the difference was not statistically significant. Larger studies are, however, unlikely to be performed because of the challenging setup, and we find the conclusions to be genuine despite nonsignificant test results. Further, we did not manage to have identical MRI protocols pre- and postoperatively for all patients. However, the lack of preoperative ^{18}F-FET PET and the use of varying MRI scanners pre- and postoperatively reflect the daily clinical routine and results from the study are thus transferable to a clinical setting.

CONCLUSION

This prospective clinical study shows PET/MRI as a powerful research tool that may help advance pediatric neurooncology in the future. Early postoperative ^{18}F-FET PET combined with MRI showed a lesionwise specificity for discriminating tumor from treatment effects of 1.00 as compared with 0.75 for MRI alone.

Consequently, if reoperation is considered on the basis of early postoperative MRI, our results support that additional ^{18}F-FET PET could help discriminate treatment effects from true residual tumor, allowing for a conservative approach instead of immediate reoperation for whom ^{18}F-FET PET does not suggest residual tumor.

REFERENCES

1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin.* 2014;64:83–103.
2. Ostrom QT, de Blank PM, Kruchko C, et al. Alex's Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. *Neuro Oncol.* 2015;16(suppl 10):x1–x36.
3. Koch SV, Kejs AM, Engholm G, Moller H, Johansen C, Schmiegelow K. Leaving home after cancer in childhood: a measure of social independence in early adulthood. *Pediatr Blood Cancer.* 2006;47:61–70.
4. Dodgshun AJ, Maixner WJ, Hansford JR, Sullivan MJ. Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. *J Neurosurg Pediatr.* 2016;17:569–572.
5. Foreman NK, Love S, Gill SS, Coakham HB. Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. *Neurosurgery.* 1997;40:856–860.
6. Bartlett F, Kortmann R, Saran F. Medulloblastoma. *Clin Oncol (R Coll Radiol).* 2013;25:36–45.
7. Albert NL, Weller M, Suchorska B, et al. Response assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol.* 2016;18:1199–1208.
8. Rapp M, Heinzel A, Galldiks N, et al. Diagnostic performance of ^{18}F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. *J Nucl Med.* 2013;54:229–235.
9. Karunanithi S, Sharma P, Kumar A, et al. Comparative diagnostic accuracy of contrast-enhanced MRI and ^{18}F-FDOPA PET-CT in recurrent glioma. *Eur Radiol.* 2013;23:2628–2635.
10. Glaudemans AW, Enting RH, Heesters MA, et al. Value of ^{11}C-methionine PET in imaging brain tumours and metastases. *Eur J Nucl Med Mol Imaging.* 2013;40:615–635.
11. Pirotte BJ, Levivier M, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. *Neurosurgery.* 2009;64:471–481.
12. Hutterer M, Nowosielski M, Putzer D, et al. [^{18}F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. *Neuro-oncol.* 2013;15:341–351.
13. Buchmann N, Klasner B, Gempt J, et al. ^{18}F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging. *World Neurosurg.* 2016;89:420–426.
14. Roessler K, Becherer A, Donat M, Cejna M, Zachenhofer I. Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography (^{18}F-FET PET) in glioblastoma surgery. *Neurol Res.* 2012;34:314–317.
15. Tscherpel C, Dunkl V, Ceccon G, et al. The use of O-(2-^{18}F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. *Neuro Oncol.* 2017;19:710–718.
16. Pirotte B, Levivier M, Morelli D, et al. Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. *Childs Nerv Syst.* 2005;21:294–300.
17. Dunkl V, Cleff C, Stoffels G, et al. The usefulness of dynamic O-(2-^{18}F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. *J Nucl Med.* 2015;56:88–92.
18. Henriksen OM, Marner L, Law I. Clinical PET/MR imaging in dementia and neuro-oncology. *PET Clin.* 2016;11:441–452.
19. Andersen FL, Ladefoged CN, Beyer T, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. *Neuroimage.* 2014;84:206–216.
20. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. *J Nucl Med.* 2009;50:520–526.
21. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[^{18}F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. *Brain.* 2005;128:678–687.
22. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. *Eur J Nucl Med Mol Imaging.* 2007;34:1933–1942.
23. Pöpperl G, Kreth FW, Herms J, et al. Analysis of ^{18}F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? *J Nucl Med.* 2006;47:393–403.
24. Law I, Albert NL, Arbizu J, et al. A joint EANM/EANO/RANO practice guideline/SNMMI procedure standard for imaging of gliomas using PET with radiolabeled amino acids and [^{18}F]FDG: version 1.0. *Eur J Nucl Med Mol Imaging.* 2019;46:540–557.
25. Gatidis S, Bender B, Reimold M, Schafer JF. PET/MRI in children. *Eur J Radiol.* 2017;94:A64–A70.
26. Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. *Clin Transl Imaging.* 2017;5:135–149.
27. Sher AC, Seghers V, Paldino MJ, et al. Assessment of sequential PET/MRI in comparison with PET/CT of pediatric lymphoma: a prospective study. *AJR.* 2016;206:623–631.
28. Willems PW, Taphoorn MJ, Burger H, Berkelbach van der Sprenkel JW, Tulleken CA. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. *J Neurosurg.* 2006;104:360–368.
29. Kurimoto M, Hayashi N, Kamiyama H, et al. Impact of neuronavigation and image-guided extensive resection for adult patients with supratentorial malignant astrocytomas: a single-institution retrospective study. *Minim Invasive Neurosurg.* 2004;47:278–283.
30. Coburger J, Scheuerle A, Kapapa T, et al. Sensitivity and specificity of linear array intraoperative ultrasound in glioblastoma surgery: a comparative study with high field intraoperative MRI and conventional sector array ultrasound. *Neurosurg Rev.* 2015;38:499–509.